BR112023003492A2 - COMPOUND OF FORMULA (I), PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND - Google Patents

COMPOUND OF FORMULA (I), PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND

Info

Publication number
BR112023003492A2
BR112023003492A2 BR112023003492A BR112023003492A BR112023003492A2 BR 112023003492 A2 BR112023003492 A2 BR 112023003492A2 BR 112023003492 A BR112023003492 A BR 112023003492A BR 112023003492 A BR112023003492 A BR 112023003492A BR 112023003492 A2 BR112023003492 A2 BR 112023003492A2
Authority
BR
Brazil
Prior art keywords
compound
formula
pharmaceutical composition
cocrystal
bronchiectasis
Prior art date
Application number
BR112023003492A
Other languages
Portuguese (pt)
Inventor
Li Yao
Shi Zongjun
Zhang Guobiao
Chen Lei
Wang Wenjing
Zhang Xiaobo
Zheng Dengyu
Xu Bo
Liu Xin
Wang Yajun
Ye Fei
TANG Pingming
Ni Jia
Zhang Chen
Yan Pangke
Original Assignee
Haisco Pharmaceuticals Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haisco Pharmaceuticals Pte Ltd filed Critical Haisco Pharmaceuticals Pte Ltd
Publication of BR112023003492A2 publication Critical patent/BR112023003492A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms

Abstract

COMPOSTO DE FÓRMULA (I), COMPOSIÇÃO FARMACÊUTICA E USO DO COMPOSTO. É divulgado um composto derivado de nitrila representado pela fórmula (I), um estereoisômero, um produto deuterado, um cocristal, um solvato ou um sal farmaceuticamente aceitável do mesmo, em que cada grupo é conforme definido na descrição. O composto tem atividade inibitória da dipeptidil peptidase 1 e pode ser usado para preparar um medicamento para o tratamento de doenças, incluindo doenças obstrutivas das vias aéreas, bronquiectasia, fibrose cística, asma, enfisema e doenças pulmonares obstrutivas crônicas.COMPOUND OF FORMULA (I), PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND. There is disclosed a nitrile derivative compound represented by formula (I), a stereoisomer, a deuterated product, a cocrystal, a solvate or a pharmaceutically acceptable salt thereof, wherein each group is as defined in the description. The compound has dipeptidyl peptidase 1 inhibitory activity and can be used to prepare a medicine for treating diseases including obstructive airway disease, bronchiectasis, cystic fibrosis, asthma, emphysema and chronic obstructive pulmonary disease.

BR112023003492A 2020-08-26 2021-08-25 COMPOUND OF FORMULA (I), PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND BR112023003492A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010871912 2020-08-26
CN202011129809 2020-10-21
CN202110167731 2021-02-07
PCT/CN2021/114500 WO2022042591A1 (en) 2020-08-26 2021-08-25 Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof

Publications (1)

Publication Number Publication Date
BR112023003492A2 true BR112023003492A2 (en) 2023-05-09

Family

ID=80354645

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023003492A BR112023003492A2 (en) 2020-08-26 2021-08-25 COMPOUND OF FORMULA (I), PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND

Country Status (13)

Country Link
US (2) US11807635B2 (en)
EP (1) EP4129989A1 (en)
JP (1) JP2023539101A (en)
KR (1) KR20230084134A (en)
CN (1) CN115996923A (en)
AU (1) AU2021330865A1 (en)
BR (1) BR112023003492A2 (en)
CA (1) CA3190610A1 (en)
CL (1) CL2023000532A1 (en)
IL (1) IL300855A (en)
MX (1) MX2023002371A (en)
TW (1) TW202214616A (en)
WO (1) WO2022042591A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022007376A (en) 2019-12-20 2022-09-02 Tenaya Therapeutics Inc Fluoroalkyl-oxadiazoles and uses thereof.
WO2023160541A1 (en) * 2022-02-22 2023-08-31 四川海思科制药有限公司 Preparation method of nitrogen-containing heterocyclic compound
WO2023160542A1 (en) * 2022-02-22 2023-08-31 四川海思科制药有限公司 Salt and crystal form of dipeptidyl peptidase inhibitor compound

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
RU2004120784A (en) 2001-12-04 2005-08-10 Ф.Хоффманн-Ля Рош Аг (Ch) SUBSTITUTED 2-AMINOCYCLOCALANOCARBOXAMIDES AND THEIR APPLICATION AS Cysteine Protease Inhibitors
US20070099958A1 (en) 2003-06-18 2007-05-03 Prozymex A/S Protease inhibitors
CA2706679A1 (en) * 2007-12-12 2009-06-18 Astrazeneca Ab Novel compounds 010
KR20120034639A (en) 2009-05-07 2012-04-12 아스트라제네카 아베 Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
US8633322B2 (en) * 2009-10-29 2014-01-21 Janssen Pharmaceutica Nv Alkynyl derivatives useful as DPP-1 inhibitors
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
WO2015032942A1 (en) * 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
NO2699580T3 (en) 2014-01-24 2018-02-24
JP6529575B2 (en) 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Substituted oxetanes and their use as inhibitors of cathepsin C
WO2016139355A1 (en) * 2015-03-05 2016-09-09 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
WO2016172496A1 (en) 2015-04-23 2016-10-27 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and uses thereof
CN107922315B (en) 2015-08-29 2021-03-26 广东东阳光药业有限公司 Cathepsin K inhibitors and uses thereof

Also Published As

Publication number Publication date
JP2023539101A (en) 2023-09-13
CL2023000532A1 (en) 2023-09-29
MX2023002371A (en) 2023-05-19
TW202214616A (en) 2022-04-16
US20240059681A1 (en) 2024-02-22
US11807635B2 (en) 2023-11-07
AU2021330865A1 (en) 2023-04-27
WO2022042591A1 (en) 2022-03-03
US20230121807A1 (en) 2023-04-20
IL300855A (en) 2023-04-01
CA3190610A1 (en) 2022-03-03
EP4129989A1 (en) 2023-02-08
KR20230084134A (en) 2023-06-12
CN115996923A (en) 2023-04-21

Similar Documents

Publication Publication Date Title
BR112023003492A2 (en) COMPOUND OF FORMULA (I), PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND
NO20061254L (en) Pharmaceutical mixtures
JP2015522616A5 (en)
AR042578A1 (en) MUCINE SYNTHESIS INHIBITORS
WO2021207409A3 (en) Small molecule inhibitors of sars-cov-2 viral replication and uses thereof
UA92181C2 (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimers disease
BR0309670A (en) Dicetohydrazine derivative compounds and drugs containing the compounds as active ingredient
NO20063693L (en) Connection and method of use
CA2905621A1 (en) Substituted aromatic compounds and related methods for the treatment of fibrosis
RU2010108640A (en) NEW COMBINATION OF THERAPEUTIC AGENTS
RS20080497A (en) Novel low dose pharmaceutical compositions comrising nimesulide, preparation and use thereof
CN107708697B (en) Therapeutic agent for fibrosis
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
JOP20200314A1 (en) Stable pharmaceutical compositions for pressurized metered dose inhalers
WO2020241759A1 (en) Prophylactic and/or therapeutic agent for influenza virus infection or corona virus infection
BRPI0716214A2 (en) PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF FUNGAL INFECTIONS.
MX2021014372A (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same.
CA2388657A1 (en) New combination comprising a beta 2 (.beta.)2 adreno receptor agonist and a leukotriene receptor antagonist
EP3209294B1 (en) Pharmaceutical composition for use in increasing the trophism of nasal mucosa
CL2022000079A1 (en) Formulations of (s)-3-amino-6-methoxy-n-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide
EP1670464B1 (en) Topical compositions comprising telmesteine for treating dermatological disorders
BR112021023445A2 (en) Pharmaceutical composition of the pyridine amine compound and its application in ros1-positive non-small cell lung cancer
EP2004176B1 (en) USE OF N- ( DIBENZ (b, f) OXEPIN-10-YLMETHYL ) N-METHYL-N- PROP- 2 -YNYLAMINE (OMIGAPIL) FOR THE PROPHYLAXIS AND / OR TREATMENT OF CONGENITAL MUSCULAR DYSTROPHY OR MYOPATHY RESULTING FROM COLLAGEN VI DEFICIENCY
BR112022012758A2 (en) COMPOUND, ISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD OF PREPARATION AND USE OF SUCH COMPOUND, PHARMACEUTICAL COMPOSITION AND HEALTHY FUNCTIONAL FOOD
CA3109212A1 (en) Synergistic drug combination of a selective cyclooxygenase-2 inhibitor and a anthraquinone derivative